PHP
TVRD

Parkman Healthcare Partners’s Tvardi Therapeutics TVRD Stock Holding History

Parkman Healthcare Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65,000
Closed -$2.53M – 111
2025
Q3 		$2.53M Buy
+65,000
New +$1.85M 0.26% 78

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Parkman Healthcare Partners's TVRD Position: Q4 2025 in Review

Parkman Healthcare Partners sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 65,000 shares — an estimated $2.53M sold.

Parkman Healthcare Partners first reported a position in TVRD in Q3 2025 and held it in 1 quarter. The position peaked at $2.53M in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • Parkman Healthcare Partners reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 65,000 Tvardi Therapeutics shares in Q4 2025, an estimated $2.53M.
  • Parkman Healthcare Partners first reported a position in Tvardi Therapeutics in Q3 2025 and held it in 1 quarter.
  • Parkman Healthcare Partners's Tvardi Therapeutics position peaked at $2.53M in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Parkman Healthcare Partners's 13F filing for Q4 2025, filed 17 Feb 2026.